Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF 0.73% Market Closed
Market Cap: 178.8m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Change in Working Capital
-CHf7.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Change in Working Capital
$45.9m
CAGR 3-Years
58%
CAGR 5-Years
102%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Change in Working Capital
CHf71.7m
CAGR 3-Years
254%
CAGR 5-Years
92%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Change in Working Capital
-$23.4m
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Change in Working Capital
CHf15.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Change in Working Capital
-CHf3.9m
CAGR 3-Years
-52%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
178.8m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
3.07 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Change in Working Capital?
Change in Working Capital
-7.1m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Change in Working Capital amounts to -7.1m CHF.

What is Molecular Partners AG's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
31%

Over the last year, the Change in Working Capital growth was 31%.

Back to Top